ESR1 and breast cancer: Regarding the use of cyclin dependent kinase 4/6 (CDK4/6) inhibitors in early-stage BC, the panel was split on the indication of adjuvant abemaciclib for high-risk ER-positive, HER2-negative LN-positive BC based on the recently published monarchE trial [23].